The pathogenesis of PVT associated with the use of COVID-19 vaccines against SARS-CoV-2 is suggested as the result of the viral proteins and free deoxyribonucleic acid in the vaccine binding to platelet factor 4 to generate a neoantigen that subsequently leads to the development of antibodies against platelet factor 4 which activate platelets and promote clotting [143]. The gene discussed is PF4; the disease is COVID-19.